Doughty J C
University Department of Surgery, Western In.rmary, Glasgow, Scotland, UK.
Breast. 2008 Jan;17 Suppl 1:S9-S14. doi: 10.1016/S0960-9776(08)70003-1.
Patients treated surgically for early breast cancer show a peak recurrence 2 years following surgery. Distant metastases are the most common recurrence event and are associated with an increased risk of dying from breast cancer within 5 years. Consequently, reducing the risk of distant metastases is an important therapeutic goal. The use of an aromatase inhibitor (AI) as initial adjuvant therapy has been shown to reduce the risk of early recurrence. The Breast International Group 1-98 primary core analysis demonstrated that letrozole is the only AI in the initial adjuvant setting to demonstrate a significant 27% reduction in early distant metastases at 25.8 months in hormone receptor-positive patients. Once patients are diagnosed with distant metastases, they have incurable disease. Developing endocrine therapies to reduce the risk of distant metastases is, therefore, critically important therapeutic goal.
接受早期乳腺癌手术治疗的患者在术后2年出现复发高峰。远处转移是最常见的复发事件，且与5年内死于乳腺癌的风险增加相关。因此，降低远处转移风险是一个重要的治疗目标。使用芳香化酶抑制剂（AI）作为初始辅助治疗已被证明可降低早期复发风险。乳腺癌国际协作组1-98的主要核心分析表明，来曲唑是初始辅助治疗中唯一一种能使激素受体阳性患者在25.8个月时早期远处转移显著降低27%的AI。一旦患者被诊断为远处转移，其疾病就无法治愈。因此，开发内分泌疗法以降低远处转移风险是至关重要的治疗目标。
